论文部分内容阅读
目的:分析帕金森病(PD)伴慢性心力衰竭(CHF)患者的心率变异性(HRV)与心功能和预后的关系。方法:选取2018年1月至2019年12月期间本院收治的PD伴CHF的患者60例为A组，选取同期收治的50例单纯PD患者为B组，同期健康体检者40例为C组。监测三组心率高频值(HF)、低频值(LF)、高频和低频比值(HF/LF)、左室射血分数值(LVEF)，记录患者随访半年期间急性冠脉综合征、恶性心律失常和急性心衰等心血管事件的发生率和死亡率。结果:C组HF、HF/LF比值及LVEF值均显著高于A、B两组，LF值显著低于A、B两组(n P<0.05)；B组HF、HF/LF比值及LVEF值均显著高于A组，LF值显著低于A组(n P<0.05)。A组LVEF≥50%患者的HF和HF/LF比值均显著高于LVEF<50%的患者，LF则显著低于LVEF<50%的患者(n P<0.05)；A组患者死亡、有心血管事件发生的患者HF和HF/LF值显著低于存活患者和无心血管事件发生患者，LF值显著高于存活患者和无心血管事件发生患者(n P<0.05)。A组患者HF值、HF/LF值与LVEF值呈正相关(n rn HF＝0.883，n rHF/n LF＝0.854，n P均<0.05)，与死亡率(n rn HF＝-0.819，n rHF/n LF＝-0.802，n P均<0.05)和心血管事件发生率(n rn HF＝-0.736，n rHF/n LF＝-0.794，n P均<0.05)呈负相关；LF值与LVEF值呈负相关(n r＝-0.743，n P<0.05)，LF值与死亡率(n r＝0.743，n P<0.05)和心血管事件发生率(n r＝0.750，n P<0.05)呈正相关。n 结论:PD伴CHF患者HRV指标降低会减弱患者心功能，增加患者的不良预后，因此HRV的指标监测有助于PD伴CHF患者的治疗和预后干预。“,”Objective:To analyze the relationship between heart rate variability (HRV) and cardiac function and prognosis in patients with Parkinson′s disease (PD) and chronic heart failure (CHF).Methods:60 patients with PD and CHF admitted to our hospital from January 2018 to December 2019 were selected as group A. 50 patients with simple PD admitted in the same period were selected as group B , and 40 patients in the healthy control group were selected as group C. The high frequency (HF), low frequency (LF), high frequency and low frequency ratio (HF/LF), left ventricular ejection fraction (LVEF) were monitored in the three groups, and the incidence and mortality of cardiovascular events such as acute coronary syndrome, malignant arrhythmia and acute heart failure were recorded during six months follow-up.Results:The HF, HF/LF ratio and LVEF of group C were significantly higher than those of group A and B, and LF value was significantly lower than that of group A and B (n P<0.05). The HF, HF/LF ratio and LVEF of group B were significantly higher than those of group A, and LF value was significantly lower than that of group A (n P<0.05). The HF and HF/LF ratio of patients with LVEF≥50% in group A was significantly higher than those with LVEF<50%, and LF was significantly lower than those with LVEF<50% (n P<0.05). The HF and HF/LF values of the patients in group A who died and had cardiovascular events were significantly lower than those of the surviving patients and those without cardiovascular events, and the LF values were significantly higher than those of the surviving patients and those without cardiovascular events (n P<0.05). The HF and HF/LF value of group A was positively correlated with LVEF value (n rn HF=0.883, n rHF/n LF=0.854, n P<0.05), and negatively correlated with mortality (n rn HF=-0.819, n rHF/n LF=-0.802, n P<0.05) and cardiovascular events (n rn HF=-0.736, n rHF/n LF=-0.794, n P<0.05) ; LF value was negatively correlated with LVEF value (n r=-0.743, n P<0.05). LF value was positively correlated with mortality (n r=0.743, n P<0.05) and the incidence of cardiovascular event (n r=0.750, n P<0.05).n Conclusions:The decrease of HRV in PD patients with CHF will weaken their cardiac function and increase their adverse prognosis. Therefore, the monitoring of HRV is helpful for the treatment and prognosis intervention in PD patients with CHF.